Canbridge Pharmaceuticals (HKSE:01228) FCF Margin % : -243.56% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Canbridge Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Canbridge Pharmaceuticals's Free Cash Flow for the six months ended in Dec. 2023 was HK$-159.4 Mil. Canbridge Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was HK$65.4 Mil. Therefore, Canbridge Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was -243.56%.

As of today, Canbridge Pharmaceuticals's current FCF Yield % is -241.78%.

The historical rank and industry rank for Canbridge Pharmaceuticals's FCF Margin % or its related term are showing as below:

HKSE:01228' s FCF Margin % Range Over the Past 10 Years
Min: -11478.04 Med: -1901.08 Max: -310.19
Current: -310.19

During the past 5 years, the highest FCF Margin % of Canbridge Pharmaceuticals was -310.19%. The lowest was -11478.04%. And the median was -1901.08%.

HKSE:01228's FCF Margin % is ranked worse than
60.52% of 1046 companies
in the Biotechnology industry
Industry Median: -141.025 vs HKSE:01228: -310.19

Canbridge Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Canbridge Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Canbridge Pharmaceuticals FCF Margin % Chart

Canbridge Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-11,478.04

-2,536.02

-1,901.08

-399.84

-310.19

Canbridge Pharmaceuticals Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial				-1,204.06	-502.08	-319.59	-402.77	-243.56

Competitive Comparison of Canbridge Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Canbridge Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Canbridge Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Canbridge Pharmaceuticals's FCF Margin % falls into.

Canbridge Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Canbridge Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-349.015	/	112.518
	=	-310.19 %

Canbridge Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-159.362	/	65.43
	=	-243.56 %

Canbridge Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Canbridge Pharmaceuticals (HKSE:01228) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (HKSE:01228) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

MF1:Germany

Address

Building 21, No. 388 Xinping Street, Unit 18, 6th Floor, Suzhou Industrial Park,, Suzhou, CHN

Website

https://www.canbridgepharma.com

Canbridge Pharmaceuticals Inc is a global biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.

Executives

Xue James Qun	2101 Beneficial owner
Athos Capital Limited	2102 Investment manager
Moskey Matthew Love	2201 Interest of corporation controlled by you
Schulte-hillen Friedrich Bela	2201 Interest of corporation controlled by you
Athos Asia Event Driven Master Fund	2101 Beneficial owner
Ctx Pharma Holdings Limited	2101 Beneficial owner
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Kolchinsky Peter	2305 Beneficiary of a trust
Ra Capital Management, L.p.	2102 Investment manager
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner
Wuxi Apptec Co., Ltd.
Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2101 Beneficial owner

Canbridge Pharmaceuticals (HKSE:01228) Headlines

No Headlines